Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive...
70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and...
TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...
MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells...
MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression...
TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company...
Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression...
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) to the tumor...
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Medicenna...
Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.13 | 7.55813953488 | 1.72 | 1.98 | 1.65 | 53155 | 1.74269414 | CS |
4 | 0.09 | 5.11363636364 | 1.76 | 2.14 | 1.6 | 61249 | 1.82263453 | CS |
12 | -0.02 | -1.06951871658 | 1.87 | 2.62 | 1.27 | 81978 | 1.98023637 | CS |
26 | -0.08 | -4.14507772021 | 1.93 | 2.62 | 1.27 | 74052 | 2.03452876 | CS |
52 | 1.405 | 315.730337079 | 0.445 | 2.98 | 0.385 | 102603 | 1.86191423 | CS |
156 | -0.42 | -18.5022026432 | 2.27 | 2.98 | 0.215 | 63535 | 1.4439818 | CS |
260 | -0.79 | -29.9242424242 | 2.64 | 7.25 | 0.215 | 73483 | 2.76585562 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.